Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?

BACKGROUND: The recent introduction of Direct Acting Antivirals (DAAs) for treating Hepatitis C Virus (HCV) can significantly assist in the world reaching the international target of elimination by 2030. Yet, the challenge facing many individuals and countries today lies with their ability to access...

Descripción completa

Detalles Bibliográficos
Autores principales: Assefa, Yibeltal, Hill, Peter S., Ulikpan, Anar, Williams, Owain D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597986/
https://www.ncbi.nlm.nih.gov/pubmed/28903757
http://dx.doi.org/10.1186/s12992-017-0297-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597986/
https://www.ncbi.nlm.nih.gov/pubmed/28903757
http://dx.doi.org/10.1186/s12992-017-0297-6

Ejemplares similares